Business
Development of New Novel siRNA Therapeutics
Development of New Novel siRNA Therapeutics.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n7 August 2023\n \nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\n \nDevelopment of New Novel siRNA Therapeutics\nPortfolio and IP position enhanced with expansion of novel siRNA medicines\n \nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market is pleased to announce the successful development of new siRNA sequences and new patent filing for its family of novel anti-cancer siRNA therapeutics.\n \nFollowing the Company's acquisition of Oncogeni Ltd in September 2022, where Roquefort Therapeutics acquired a portfolio of pioneering pre-clinical siRNA anti-cancer medicines with significant in vivo efficacy, the Company's drug discovery team, led by Vice President of Drug Discovery, Professor Graham Robertson, has recently developed four additional siRNA sequences to complement the existing siRNA portfolio. The new siRNA sequences expand the Company's portfolio of siRNA medicines that attack the targets STAT-6 (Signal Transducer and Activator of Transcription)[1] and its SH2 (Src-homology-2) domain[2].\n \nThe Company has recently completed a new patent filing to strengthen its siRNA patent position to protect both the composition of matter and methods of use.\n \nsiRNA therapeutics are an innovative new class of medicines based on RNA interference (RNAi), which was recognized with the 2006 Nobel Prize in Medicine or Physiology and pioneered by a leading biotech company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) which recently completed a $2.8 billion partnership with Roche (SWX: ROG)[3].\n \nThe siRNA targets STAT-6 and SH2 were recently validated by Sanofi (NASDAQ: SNY) in a licensing transaction with Recludix that included a US$125 million upfront payment and represented a total deal value of up to US$1.2 billion[4] for a program in the pre-clinical stage of development that targets the SH2 domain of STAT6. Roquefort Therapeutic's siRNA programs are also in pre-clinical development and target STAT-6 and the SH2 domain and have shown significant in vivo anti-cancer activity (*p<0.05) in validated models of colon cancer[5].\n \nThe Company's siRNA sequences are being developed in combination with nano-particle delivery sy...